LLADTTHHRPWT

This peptide, termed BRP [bevacizumab responsive peptide], has been identified by phage display selection (Cao et al, 2011). The peptide is metabolically stable and has low toxicity to both endothelial cells and tumor cells. It acts as a homing peptide and shows strong binding to tumors treated with bevacizumab, but not to untreated control LS174T tumors. The peptide shows specificity for bevacizumab-treated tumor vasculature, and radiolabelled peptide can be used as a probe for imaging early response to anti-angiogenic bevacizumab treatment.

Hardy et al (2000) have identified the same peptide by phage selection as ... ... ... ... ... Subscribe to continue reading! ... ...